Zentralbl Chir 2015; 140(06): 607-609
DOI: 10.1055/s-0032-1328737
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Rezidive nach zytoreduktiver Chirurgie und hyperthermer intraperitonealer Chemotherapie (HIPEC) beim kolorektalen Karzinom

Recurrent Peritoneal Metastases after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer
I. Königsrainer
Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie Tübingen, Deutschland
,
F. Struller
Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie Tübingen, Deutschland
,
D. Zieker
Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie Tübingen, Deutschland
,
A. Königsrainer
Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie Tübingen, Deutschland
,
S. Beckert
Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie Tübingen, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
11 July 2013 (online)

Zusammenfassung

Einleitung: Peritoneale Rezidive nach zytoreduktiver Chirurgie (ZRC) und hyperthermer intraperitonealer Chemotherapie (HIPEC) beim peritoneal metastasierten kolorektalen Karzinom sind eine besondere Herausforderung für die chirurgische und konservative Onkologie. Methoden: Anhand der Literatur werden aktuelle chirurgische Konzepte diskutiert. Resultate: Die Mehrzahl der Patienten erleidet nach ZRC und HIPEC ein Rezidiv. Die häufigste Konsequenz ist eine palliative Chemotherapie. Inwieweit bei selektionierten Patienten eine Re-Operation mit erneuter ZRC und HIPEC gerechtfertigt ist, wird diskutiert. Schlussfolgerung: Neue Konzepte sind notwendig, um Patienten mit einem peritonealen Rezidiv möglichst frühzeitig behandeln zu können.

Abstract

Background: Peritoneal recurrences after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer are challenges in conservative and surgical oncology. Methods: Surgical concepts are discussed in this review on the basis of the current literature. Results: The majority of patients suffer from recurrent disease after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer. In most cases, a palliative chemotherapy is performed. Repeated surgery with the aim of complete cytoreduction may be done in selected cases. Conclusions: New concepts are necessary to treat patients with recurrent disease as early as possible.

 
  • Literatur

  • 1 Glehen O, Gilly FN, Boutitie F et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010; 116: 5608-5618
  • 2 Chua TC, Yan TD, Smigielski ME et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 2009; 16: 1903-1911
  • 3 Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?. Ann Surg 2008; 248: 829-835
  • 4 Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743
  • 5 Verwaal VJ, Bruin S, Boot H et al. Eight-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432
  • 6 Feldman AL, Libutti SK, Pingpank JF et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560-4567
  • 7 Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003; 21: 233-248
  • 8 Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003; 13: 764-770
  • 9 Bijelic L, Yan TD, Sugarbaker PH. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 2007; 14: 2281-2288
  • 10 Königsrainer I, Horvath P, Struller F et al. Risk factors for recurrence following complete cytoreductive surgery and HIPEC in colorectal cancer-derived peritoneal surface malignancies. Langenbecks Arch Surg 2013; 398: 745-749
  • 11 Verwaal VJ, Boot H, Aleman BM et al. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol 2004; 11: 375-379
  • 12 Elias D, Goéré D, Di Pietrantonio D et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008; 247: 445-450
  • 13 Weber T, Link K. Kolonkarzinom: Aktueller Stand der multimodalen Therapie. Zentralbl Chir 2011; 136: 325-333